Showing results (101-110 of 137) with videos related to
Sort By:
Pageof 14
Health Science Reports|April 3, 2019
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II)Tarik Asselah, Negar Niki Alami, Christophe Moreno, et al.Antioxidants (Basel, Switzerland)|February 25, 2022
Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort)Tangui Barré, Hélène Fontaine, Stanislas Pol, et al.Gastroenterology|July 2, 2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infectionPatrick Marcellin, Curtis Cooper, Luis Balart, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 6, 2025
Features and Outcomes of 280 Patients With Idiosyncratic Drug-induced Liver Injury: The REFHEPS Prospective StudyLucy Meunier, Bénédicte Delire, Eleonora De Martin, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 9, 2017
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programmeChristophe Hézode, Pascal Lebray, Victor De Ledinghen, et al.Journal of Hepatology|March 15, 2012
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirinDominique Larrey, Ansgar W Lohse, Victor de Ledinghen, et al.Drug Safety|January 18, 2013
Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT studySinem Ezgi Gulmez, Dominique Larrey, Georges-Philippe Pageaux, et al.Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized studyTarik Asselah, Stanislas Pol, Christophe Hezode, et al.Clinics and Research in Hepatology and Gastroenterology|June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohortAnais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.Pageof 14